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Objective: Carotid angioplasty and stenting (CAS) is a percutaneous alternative to carotid endarterectomy (CEA) for
treating patients with carotid artery stenosis. This study sought to evaluate whether patients at increased perioperative
risk for CEA may be treated with CAS while maintaining equivalent outcomes.
Methods: This study was a nonblinded, retrospective analysis of data obtained from September 2002 to present in the CAS
group and from January 1997 to present in the CEA group. Two hundred thirty-one CAS and 647 CEA procedures were
performed. Patients were selected for CAS based on criteria that placed them at increased risk for standard CEA surgery.
Except for percentage women treated, baseline demographics did not differ between patients treated with CAS and CEA:
mean age (72.0 years [range 46-94] vs 70.5 years [range 42-92], PNS), mean follow-up (12.8 11.8 months vs 8.7
10.0 months, P  NS) and percentage women treated (41.4% vs 32.3%, P  .03). Cerebral protection devices were used
in 228/231 patients treated with CAS, and each patient underwent an NIH Stroke Scale assessment 24 hours
postoperatively and at 30 days follow-up by an independent observer.
Results: Preoperative neurologic symptoms did not differ between patients treated with CAS and CEA: amaurosis fugax
(6.06% vs 6.96%, P  NS), transient ischemic attacks (13.4% vs 13.9%, P  NS), strokes (19.9% vs 14.1%, P  NS) and
total symptoms (27.7% vs 30.5%, P  NS). Due to the selection of patient groups based on predefined clinical
characteristics, factors associated with an increased risk of complications from standard CEA surgery were generally more
prevalent in patients treated with CAS: neck irradiation (6.06% vs 1.24%, P < .001), neck dissection for cancer therapy
(7.8% vs 1.5%, P < .001), prior ipsilateral CEA (15.2% vs 3.4%, P < .001), contralateral carotid artery occlusion (12.1%
vs 1.1%, P< .001), modified Goldman Cardiac Risk II-moderate risk (26.0% vs 11.3%, P< .001) and modified Goldman
Cardiac Risk III-high risk (16.4% vs 2.1%, P < .001) in patients treated with CAS and CEA, respectively. Perioperative
outcomes did not differ between patients treated with CAS and CEA: myocardial infarction (MI) (1.7% vs 2.6%, PNS),
stroke without residual symptoms (1.3% vs 1.2%, P  NS), stroke with residual symptoms (0.4% vs 0.8%, P  NS),
mortality (0.4% vs 0.6%, P  NS), and total MI/stroke/mortality rate (3.9% vs 5.3%, P  NS).
Conclusions: The data in this study demonstrate that high-risk patients undergoing CAS had comparable outcomes to
low-risk patients undergoing CEA. This study supports the use of CAS as a reasonable alternative for patients at increased
perioperative risk for CEA. (J Vasc Surg 2008;47:946-51.)The treatment of extracranial carotid artery occlusive dis-
ease is intended to decrease the risk of stroke. Prospective
randomized controlled trials have provided level I evidence to
support the use of carotid endarterectomy (CEA) as standard
therapy for achieving durable freedom from stroke in symp-
tomatic and asymptomatic patients.1-5 However, these trials
excluded patients that exhibited risk factors associated with
increased complication rates for patients undergoing CEA.
These risk factors included clinically significant cardiopulmo-
nary disease, contralateral carotid artery occlusion, recurrent
carotid artery stenosis, previous neck external radiation ther-
apy (XRT), previous neck surgery, and age greater than 80
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946years old. In response to the lack of data in patients exhibiting
these risk factors, observational reports were conducted that
preliminarily demonstrated the safety of CEA in these high-
risk patient cohorts.6-15 Nevertheless, multi-institutional and
Medicare analyses have demonstrated increased complication
rates in these high-risk patients when they are treated with
CEA.16-18
Carotid angioplasty and stenting (CAS) is a percutane-
ous procedure for treating patients with carotid stenosis,
and it has emerged as a potential alternative therapy for
patients that are at increased risk for CEA.19,20 Advantages
include the avoidance of general anesthesia, lack of a neck
incision, and lessening risk for cranial nerve injury and
wound complications.21
For patients treated with CAS, increased procedural risk
appears to result from patient age greater than 80 years old,
adverse lesion characteristics including stenosis of greater than
85%, calcification throughout the lesion, and increased lesion
length, and adverse access vessel characteristics including aor-
tic arch calcification, innominate or common carotid artery
stenosis, and common carotid and internal carotid artery
tortuosity.22-24 This study sought to evaluate whether pa-
tients at increased perioperative risk for CEA may be treated
with CAS while maintaining equivalent outcomes.
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Data for this study were derived from a joint institution,
prospectively maintained database fromNovember 2002 to
present in the CAS group and from January 1997 to present
in the CEA group. This study was a nonblinded, retrospec-
tive analysis, and patients were selected for CAS based on
criteria that placed them at increased risk for standard CEA
surgery. The internal review board and ethics committee
approved the study protocol.
Investigators
Data from all vascular surgeons at the participating
institutions were included. All of the surgeons had per-
formed greater than 25 CEAs; and of the investigators
performing CAS, all had performed greater than 25 inter-
ventions with at least one half as primary operator.
Patients
CAS. Two hundred thirty-one CAS procedures were
performed on 215 patients. Patients were selected preferen-
tially for CAS based on a history of neck XRT, neck dissection
for cancer therapy, recurrent carotid artery stenosis, contralat-
eral carotid artery occlusion, and a history of severe cardiopul-
monary disease as evidenced by elevated modified Goldman
Table I. Preoperative characteristics
Characteristic
CAS
N  231
CEA
N  647 P value
Percentage
Preoperative symptoms
Urgent operations 6.6 3.6 .11
Total symptoms 27.7 30.5 .06
Amaurosis fugax 6.1 7.0 .75
Transient ischemic attack 13.4 13.9 .94
Stroke 19.9 14.1 .09
Preoperative cardiac history
NYHA Angina III 34.8 7.0 .001
NYHA Angina IV 3.4 0.7 .02
Edema 20.9 5.2 .001
Aortic stenosis 5.4 0.5 .001
Arrhythmia 49.0 8.7 .001
Premature ventricular
contractions
26.5 0.5 .001
CABG 23.4 9.6 .001
Preoperative noncardiac history
Hypertension 87.6 76.5 .001
Hyperlipidemia 67.1 53.2 .001
Peripheral vascular disease 22.5 31.0 .02
Neck XRT 6.1 1.2 .001
Neck dissection for cancer 7.8 1.5 .001
Recurrent stenosis 15.2 3.4 .001
Contralateral occlusion 12.1 1.1 .001
CABG,Coronary artery bypass graft;CAS, carotid angioplasty and stenting;
CEA, carotid endarterectomy; COPD, chronic obstructive pulmonary dis-
ease; NYHA Angina III, New York Heart Association Angina Class III:
Marked limitation of ordinary physical activity. Walking one to two blocks
on the level and climbing more than one flight in normal conditions; NYHA
Angina IV, New York Heart Association Class IV: Inability to carry on any
physical activity without discomfort - anginal syndrome may be present at
rest; neck XRT, neck external radiation treatment.Cardiac Risk Scores (Tables I and II). Percentage stenosis wasdetermined byNorth American Symptomatic Carotid Endar-
terectomy Trial (NASCET) angiographic criteria;1 59% of
CASprocedureswere performed either as part of a clinical trial
or a postmarket registry.
CEA. Six hundred forty-seven CEA surgeries were per-
formed on 575 patients. Patients selected for CEA preferen-
tially lacked a history of neck XRT, neck dissection for cancer
therapy, recurrent carotid artery stenosis, contralateral carotid
artery occlusion, and had lower modified Goldman Cardiac
Risk Scores (Tables I and II). In addition, during the initial
angiographic evaluation of the CAS procedure, anatomic and
lesion criteria were evaluated to determine if the patient was at
high risk for undergoing CAS. Two patients were selected for
CEA and one patient for transcervical CAS due to unfavorable
anatomic characteristics, including bovine arch anatomy and
excessive internal carotid artery (ICA) tortuosity. Preoperative
percentage carotid artery stenosis was measured routinely by
duplex ultrasonography, magnetic resonance angiography
(MRA) or both. In rare and equivocal cases amounting to
3.4% of patients treated with CEA, percentage stenosis was
measured by conventional angiography using NASCET
criteria.
Procedures
CAS. Endovascular procedures were performed by
vascular surgeons in an operating room angiography suite
equipped with a fixed imaging system (Siemens AG,Munich,
Germany). Local anesthetic without sedation and femoral
access were used in all cases. A self-expanding stent was
deployed in each CAS procedure, and emboli-protection
devices were employed in all but three cases (Table III).
Perioperative anticoagulation for patients treated with CAS
is described in Table IV.
CEA. Vascular surgeons performed the surgeries us-
ing standard technique.25 Anesthetic and intraoperative
parameters were as follows: general anesthesia 95.8%, cer-
vical block 4.2%, shunt 19.7%, electroencephalogram 75%,
and carotid artery patching 99.1%. Perioperative anticoag-
ulation for patients undergoing CEA consisted of intraop-
erative heparinization with goal ACT of 250-350 and aspi-
rin 81 mg daily.
Follow-up
Each patient underwent an independent National In-
stitutes of Health Stroke Scale (NIHSS) assessment post-
operatively by a neurologist or a NIHSS certified provider.
Table II. Modified Goldman Cardiac Risk Score
Modified Goldman cardiac
risk scores
CAS
N  231
CEA
N  647 P value
Percentage
I  Low risk (0-15) 57.5 86.7 .001
II Moderate risk (20-30) 26.0 11.3 .001
III  High risk (30) 16.4 2.1 .001
CAS, Carotid angioplasty and stenting; CEA, carotid endarterectomy.A neurologist confirmed each documented stroke. Postop-
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months, as well as annually thereafter. Carotid duplex
studies were performed at each follow-up visit. Follow-up
time averaged 12.8 11.8 months in patients treated with
CAS and 8.7 10.0 months in patients treated with CEA,
P  NS.
Perioperative endpoints
Primary endpoints included stroke, which was divided
into deficits resolving within 72 hours and deficits with
residual symptoms persisting beyond 72 hours; myocardial
infarction (MI), which was diagnosed by cardiac enzyme
elevation and electrocardiogram; mortality and the total
combined MI, stroke and mortality rate. Secondary end-
points included cranial nerve injury, neck hematoma,
wound infection, groin hematoma, groin pseudoaneurysm,
and late restenosis. With the exception of late restenosis,
primary and secondary endpoints were only included if they
occurred within 30 days of the procedure.
Statistical analysis
2 with Yates’ correction was performed for all discrete
variables, and unpaired t tests were used for all normally
distributed continuous variables using SPSS ver. 15.0 for
Windows (Microsoft, Chicago, Ill). All values are repre-
sented as a mean  standard deviation where applicable.
Table III. Self expanding stents and emboli protection
devices
Device Percentage
Acculink (Abbott Laboratories, Abbott Park, Ill) 56.7
NexStent (Boston Scientific Corp, Natick, Mass) 8.7
Precise (Cordis Corporation, Miami Lakes, Fla) 12.6
Wallstent (Boston Scientific Corp) 17.7
Xact (Abbott Laboratories, Chicago, Ill) 4.3
Emboli protection devices
Accunet (Abbott Laboratories) 39.0
Angioguard (Cordis Corporation) 11.7
Emboshield (Abbott Laboratories) 3.9
EPI FilterWire (Boston Scientific Corp) 27.7
PercuSurge (Medtronic, Santa Rosa, Calif) 15.2
SpiderFX (EV3 Inc, Plymouth, Minn) 1.3
Table IV. Carotid angioplasty and stenting
anticoagulation protocol
CAS anticoagulation protocol
Aspirin 81 mg po q d, started 72 h preoperatively and continued
4 weeks
Clopidogrel 75 mg po q d, started 5 days preoperatively and
continued 4 weeks
Intraoperative heparinization with goal ACT 250-350
CAS, Carotid angioplasty and stenting.P  .05 is considered statistically significant.RESULTS
Demographics
A significant difference in mean age was not observed
between patients treated with CAS and CEA (72.1  9.9
years [range 46-94] vs 70.5 9.1 years [range 42-92], P
NS). The percentage of women treated with CAS was
greater than the percentage of women treated with CEA
(41.4% vs 32.3%, P  .03). The percentage of right-sided
procedures did not differ between patients treated with
CAS and CEA (49.8% vs 46.2%, P  NS).
Preoperative characteristics
Due to the selection of patient groups based on pre-
defined clinical characteristics, factors associated with an
increased risk of complications from standard CEA surgery
were generally more prevalent in patients treated with CAS.
Significant differences in preoperative symptomatology
were not present between patients treated with CAS and
CEA: amaurosis fugax (6.1% vs 7.0%, P  NS), transient
ischemic attacks (13.4% vs 13.9%, P  NS), preoperative
strokes (19.9% vs 14.1%, P  NS) and total neurological
symptoms (27.7% vs 30.5%, P  NS). Additionally, a
significant difference was not noted for patients who un-
derwent urgent CAS or CEA for crescendo symptoms
(CAS 6.6% vs CEA 3.6%, P  NS) (Table I).
The following represent risk factors for surgery that
were more prevalent in patients treated with CAS com-
pared with CEA: hypertension (87.6% vs 76.5%, P .001),
hyperlipidemia (67.1% vs 53.2%, P  .001), neck XRT
(6.1% vs 1.2%, P .001), neck dissection for cancer therapy
(7.8% vs 1.5%, P .001), and prior ipsilateral CEA (15.2%
vs 3.4%, P  .001). A history of peripheral vascular disease
(PVD), however, was more prevalent in patients treated
with CEA (CAS 22.5% vs CEA 31.0%, P  .02) (Table I).
With respect to preoperative lesion characteristics, pa-
tients treated with CAS presented more frequently with a
contralateral occlusion (12.1% vs 1.1%, P  .001), and
patients treated with CEA presented more frequently with
bilateral carotid artery stenosis greater than 50% (31.3% vs
59.7%, P .001). Preoperative percentage stenosis did not
differ between patients treated with CAS and CEA (88.1
11.2 vs 79.3  15.2, P  NS). Specific to those patients
treated with CAS, 17.7% had bovine variant aortic arch
anatomy.
Preoperative cardiac history revealed the greatest dis-
parity between patients treated with CAS and CEA: NYHA
class III angina (34.8% vs 7.0%, P .001), NYHA class IV
angina (3.4% vs 0.7%, P .02), history of edema (20.9% vs
5.2%, P  .001), aortic stenosis (5.4% vs 0.5%, P  .001),
history of any arrhythmia (49.0% vs 8.7%, P  .001),
history of premature ventricular contractions (PVCs)
(26.5% vs 0.5%, P .001), and history of coronary artery
bypass grafting (CABG) (23.4% vs 9.6%, P  .001) (Table
I). This reflected directly in the composite modified Gold-
man Cardiac Risk Scores, which predict the risk for periop-
erative complications from surgery (ie, cardiac death, intra-
operative or postoperative MI, pulmonary edema and
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treated with CAS were more frequently in the moderate
and high-risk categories compared to patients treated with
CEA: Goldman II-moderate risk (26.0% vs 11.3%, P 
.001) and Goldman III-high risk (16.4% vs 2.1%, P 
.001).
Perioperative endpoints
CAS. Successful completion of CAS occurred in
98.7% of cases. Three patients failed to undergoCAS due to
unfavorable anatomic characteristics, including bovine arch
anatomy and excessive ICA tortuosity. Two of the patients
subsequently underwent CEA, and one patient underwent
transcervical CAS. Vascular access site complications for
patients treated with CAS included seven (3.0%) groin
hematomas that resolved spontaneously and two (0.9%)
common femoral artery pseudoaneurysms that were treated
with thrombin injection. Late restenosis of the treated
carotid artery requiring reintervention occurred in one
(0.4%) patient.
CEA. Surgical site complications in patients treated
with CEA included one (0.2%) wound infection that re-
solved with superficial drainage of the cervical incision, four
(0.6%) cranial nerve palsies that resolved within 6 months
of surgery, and ten (1.5%) neck hematomas, two (0.3%) of
which required operative evacuation. Late restenosis re-
quiring reintervention occurred in 10 (1.5%) patients.
Statistically significant differences were not observed in
the primary endpoints between patients treated with CAS
and CEA: MI (1.7% vs 2.6%, PNS), total stroke (1.7% vs
2.0%, P  NS), stroke without residual symptoms after 72
hours (1.3% vs 1.2%, P  NS), stroke with residual symp-
toms after 72 hours (0.4% vs 0.8%, P  NS), mortality
(0.4% vs 0.6%, P  NS) and total MI/stroke/morality
(3.9% vs 5.3%, P  NS) (Table V).
DISCUSSION
Randomized controlled trials have established CEA as
the standard therapy for extracranial carotid artery occlusive
disease in conventional-risk patients.1-5 The original trials
excluded patients with anatomic and physiologic factors
that were associated with increased complication rates from
surgery. Patients with the following anatomic factors were
Table V. Primary endpoints
Perioperative events
CAS
N  231
CEA
N  647 P value
Percentage
Total MI 1.7 2.6 .26
Total stroke 1.7 2.0 .79
No residual symptoms 1.3 1.2 .94
Residual symptoms 0.4 0.8 .94
Mortality 0.4 0.6 .74
Total MI/stroke/mortality 3.9 5.3 .37
CAS, Carotid angioplasty and stenting; CEA, carotid endarterectomy; MI,
myocardial infarction.preferentially excluded from the cited trials: contralateralcarotid artery occlusion, recurrent stenosis, neck XRT, neck
dissection, and lesions distal to C2. Similarly, patients with
the following physiologic factors were preferentially ex-
cluded: age greater than 80 years old and severe cardiopul-
monary disease as measured by the modified Goldman
Cardiac Risk Score.
CAS has emerged as a percutaneous alternative to treat
extracranial carotid artery stenosis in patients at increased
risk for standard CEA surgery. Advantages to CAS include
the avoidance of general anesthesia, the elimination of a
neck incision and a potential reduction in periprocedural
hemodynamic fluctuation. Disadvantages to CAS include
the risk of stroke, sparse data on long-term durability, and
access site complications.21
Patients with factors determined to increase the periop-
erative risk of standard CEA surgery such as prior neck
XRT, re-operation, and an elevated modified Goldman
Cardiac Risk Score can be treated successfully with CAS
while achieving complication rates equivalent to CEA.
Such factors may have a more limited role in influencing
periprocedural risk in patients treated with CAS. This was
partially demonstrated in the Stenting and Angioplasty
with Protection in Patients at High Risk for Endarterec-
tomy (SAPPHIRE) trial, which compared CAS with
cerebral protection to endarterectomy in patients with
moderate-to-severe stenosis and associated cardiopulmo-
nary comorbidities. The SAPPHIRE trial demonstrated
improved periprocedural outcomes for patients treated us-
ing CAS with cerebral protection compared with standard
CEA surgery in high surgical risk patients with respect to
the outcomes of MI, stroke and mortality.20
Successful use of CAS is predicated on avoiding specific
procedural risk factors including age greater than 80 years
old, aortic arch calcification, aortic arch elongation or dis-
tortion, innominate or common carotid artery stenosis, and
common carotid or internal carotid artery tortuosity. In
patients treated with CAS, the incidence of high-risk anat-
omy and of combinedMI, stroke and death are increased in
octogenarians compared with patients less than 80 years
old.22-24 The presence of unfavorable anatomic and lesion
characteristics may contribute to poor outcomes with CAS,
likely due to the increased technical difficulty of the proce-
dure. For example, tortuosity and stenosis of access vessels
may complicate sheath positioning, and the increased cath-
eter manipulation and repeated endothelial injury may in-
crease the risk for stroke. Tortuosity of the internal carotid
artery may increase the difficulty of positioning the emboli
protection device, preventing complete vessel wall apposi-
tion and decreasing the efficacy of the device at capturing
embolic particles. Lesions evaluated by B-mode ultrasound
and determined to have echolucent plaque with a gray-scale
median score of less than 25 have been reported to be more
friable and prone to dislodgement of emboli.27 Increased
lesion length has also been associated with an increased risk
for stroke in patients treated with CAS.28, 29
The current study compared patients treated with CAS
to patients treated with standard CEA surgery. Patients
considered to be at increased risk for CEA based on a
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recurrent carotid artery stenosis, contralateral carotid artery
occlusion, and who had severe cardiopulmonary disease as
evidenced by elevated modified Goldman Cardiac Risk
Scores, were preferentially treated with CAS. Age greater
than 80 years old was not used as a selection criterion that
prohibited treatment with CAS. However, during the CAS
procedure anatomic and lesion criteria were evaluated to
determine the potential to increase the risk of the proce-
dure. Utilizing this strategy there was a 98.7% procedural
success rate for CAS, with two patients subsequently un-
dergoing CEA and one patient subsequently undergoing
transcervical CAS. Overall, surgical site, vascular access site,
and perioperative morbidity and mortality occurred with
low frequencies and did not differ significantly between
patients treated with CAS and CEA. Bleeding complica-
tions occurred with similar frequencies in patients treated
with CAS or CEA. No cranial nerve injuries were reported
in patients treated with CAS, therefore they occurred with
significantly greater frequency in patients treated with
CEA, despite the low frequency of 0.6%. Additionally,
patients treated with CAS or CEA did not exhibit signifi-
cant differences in the primary endpoints of MI, stroke,
mortality, and total combined MI, stroke, and mortality
rates.
This study has the limitation that it was a retrospective
analysis. As a result, the patients were not prospectively
randomized to treatment groups, and they were subject to
selection bias. In particular, patients treated with CAS were
selected based on predefined clinical criteria that placed
them at increased risk for CEA. Nevertheless, PVD was still
more prevalent in patients treated with CEA. In patients
treated with CEA, the short average follow-up was discor-
dant with the duration of the study and therefore should be
enhanced. Additionally, the study period for patients
treated with CEA was longer compared with patients
treated with CAS, generating a larger patient cohort and
potentially confounding the data. Over the course of the
study the treatment of CEA remained relatively constant in
terms of technique and anesthesia, and the surgeons re-
mained the same. Therefore, the authors believe that addi-
tional value was gained by the inclusion of “earlier patients”
in the CEA patient cohort. In patients treated with CAS,
the variation in stents and cerebral protection devices used
introduced additional bias and diminished the power of the
statistical analysis.
To conclude, the low incidence of events in the current
study and the previously demonstrated utility of CAS and
CEA lend support to the strategy of treating patients at
increased risk for standard CEA surgery with CAS. Ulti-
mately, long-term freedom from stroke and stroke-related
death is the true gauge of success, and further study is still
needed.
CONCLUSION
The data in this study demonstrate that high-risk pa-
tients treated with CAS achieve comparable outcomes to
low-risk patients treated with CEA. Examples of perioper-ative factors that increase the risk for standard CEA surgery
include contralateral carotid artery occlusion, recurrent
stenosis, neck XRT, neck surgery, and an elevated modified
Goldman Cardiac Risk Score. Similarly, successful use of
CAS is predicated on avoiding perioperative complications,
particularly stroke. Procedural risk factors specific to CAS
including age greater than 80 years old, aortic arch calcifi-
cation, access vessel tortuosity, and stenosis as well as ICA
tortuosity may increase the technical difficulty of CAS and
therefore may increase periprocedural risk. Limiting the
impact of unfavorable anatomic features appears to be
important to the successful use of CAS. This study supports
the use of CAS as a reasonable alternative for patients at
increased perioperative risk for CEA.
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